Regeneron Pharmaceuticals (REGN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Regeneron Pharmaceuticals

NasdaqGS•Healthcare•Biotechnology

$973.36+12.10(0.01%)After hours

Market Cap

$97.76B

P/E

20.3x

P/S

5.8x

P/B

2.9x

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.

How this company scores

GoodMetricSide Score: 78/100

Strongest: Growth (23/25); weakest: Cash & Earnings Quality (16/25).

Profitability20/25

Growth23/25

Balance Sheet & Red Flags19/25

Cash & Earnings Quality16/25

Strengths

Growing revenueStrong marginsLow leverageConsistent free cash flow

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 20.3x5y range 8.4x – 27.1x

Currently near its 20-quarter median.

P/S · 5.8x5y range 3.9x – 8.4x

Currently near its 20-quarter median.

P/B · 2.9x5y range 1.8x – 4.0x

Currently near its 20-quarter median.

Price & Volume

Market Cap $97.76B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $16.90B
Q. Revenue: $5.12B
TTM EBITDA: $5.65B
TTM Op. Income: $4.86B
Q. Op. Income: $2.05B
TTM Net Income: $4.82B
Q. Net Income: $1.95B
EPS: $19.16
Shares Out.: $101.70M

$16.90B in TTM revenue grew 18.6% YoY, reaching $5.12B last quarter. TTM EBITDA of $5.65B and TTM operating income of $4.86B show growth is flowing through to the bottom line. TTM net income of $4.82B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 6 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 42.4%
Op. Margin: 40.0%
Net Margin: 38.1%

Op. margin of 40.0% is up 12.7% YoY — cost efficiency is improving. Net margin at 38.1% Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 20.3x
P/S Ratio: 5.8x
P/B Ratio: 2.9x

At 20.3x P/E, the stock trades within typical market levels. P/S of 5.8x and P/B of 2.9x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 60% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $44.41B
Cash: $3.66B
Long-Term Debt: $1.99B
Book Value: $33.50B
D/E Ratio: 0.1
Debt/EBITDA: 0.9

With $44.41B in assets and $1.99B in long-term debt, D/E is 0.1and book value is $33.50B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 7 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $1.78B
TTM Free Cash Flow: $3.83B
FCF Margin: 22.6%
FCF / Net Income: 0.8

TTM FCF of $3.83B on $1.78B in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 9% — an improving trend.